ReviewChemical biology & drug design2026
Integrating Artificial Intelligence Into Drug Discovery From Medicinal Plants: Current Applications and Infrastructural Challenges.
Review in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants represent a vast and evolutionarily refined reservoir of structurally diverse bioactive compounds that have historically contributed to major therapeutic breakthroughs. However, despite their pharmacological richness, systematic translation of plant-derived metabolites into clinically approved drugs remains constrained by persistent bottlenecks, including extract complexity, dereplication redundancy, structural elucidation challenges, taxonomic ambiguity, and multi-component pharmacology. This review presents a bottleneck-driven and systems-oriented framework for integrating artificial intelligence (AI) into medicinal plant-based drug discovery (MPDD) to address some of these bottlenecks. Rather than reiterating broadly documented AI tools used in synthetic drug development, the manuscript critically examines phytomedicine-specific challenges and maps AI applications across key stages of the pipeline: medicinal plant identification, extraction optimization, plant metabolite identification and dereplication, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, virtual screening, network pharmacology, repurposing, and generative de novo design of pseudo-natural products. Emphasis is placed on the foundational requirement of making phytochemical datasets truly AI-ready through metadata harmonization, dataset balancing, novelty-aware modeling, and structured data engineering. Emerging approaches such as transformer-based foundational models, graph neural networks (GNNs), generative AI (GAI) architectures, and multi-omics-integrated network pharmacology are discussed within a pragmatic translational context. Importantly, this review maintains a balanced perspective, acknowledging that fully AI-driven clinically approved botanical drugs/synthetic drugs have yet to emerge and identifies challenges limiting the progress. By integrating computational methods with infrastructural reform, this work outlines a progressive roadmap to transition AI in medicinal plant research from exploratory studies toward standardized, reproducible, and biologically grounded next-generation drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.